公开(公告)号：US20240360187A1

公开(公告)日：2024-10-31

申请号：US18545392

申请日：2023-12-19

申请人： UNIVERSITÄT BERN

发明人： Achim STOCKER

IPC分类号： C07K14/47 ,  A61K9/14 ,  A61K9/51 ,  A61K38/00 ,  A61K38/17 ,  A61K47/50 ,  A61P3/02 ,  A61P19/02 ,  A61P21/00 ,  A61P25/14 ,  A61P29/00 ,  B82Y5/00 ,  B82Y40/00

CPC分类号： C07K14/47 ,  A61K9/146 ,  A61K9/51 ,  A61K38/1709 ,  A61K47/50 ,  A61P3/02 ,  A61P19/02 ,  A61P21/00 ,  A61P25/14 ,  A61P29/00 ,  B82Y5/00 ,  B82Y40/00 ,  A61K38/00

摘要： The present invention relates to a nanosphere comprising an equal number of a human SEC14-like protein and a cognate ligand of said SEC14-like protein as well as to methods of producing the same and uses of said nanospheres.

公开(公告)号：US12049448B2

公开(公告)日：2024-07-30

申请号：US17871065

申请日：2022-07-22

申请人： PRAXIS PRECISION MEDICINES, INC.

发明人： Kiran Reddy ,  Margaret S. Lee ,  Gabriel Maurice Belfort ,  Sapna Makhija Garad ,  Mahesh Padval ,  Randall Wagner ,  Marion Wittmann

IPC分类号： C07D211/34 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26

CPC分类号： C07D211/34 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26 ,  C07B2200/13

摘要： Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

公开(公告)号：US20240247272A1

公开(公告)日：2024-07-25

申请号：US18444881

申请日：2024-02-19

申请人： KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Dae Soo KIM ,  Jin Kuk KIM ,  Ye Won LEE ,  Eun Ji JUNG ,  Min Sung PARK ,  Sin Jeong LEE ,  Su Jin CHAE

IPC分类号： C12N15/113 ,  A61P25/08 ,  A61P25/14 ,  A61P25/22 ,  A61P25/24 ,  A61P25/26

CPC分类号： C12N15/1138 ,  A61P25/08 ,  A61P25/14 ,  A61P25/22 ,  A61P25/24 ,  A61P25/26 ,  C12N2310/11 ,  C12N2310/3125 ,  C12N2310/313 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/341

摘要： The present invention provides antisense oligonucleotides for the treatment of various T-type calcium channel α1G subunit-related disorders, and more specifically, antisense oligonucleotides for inhibiting expression of the gene encoding Cav3.1, targeting SEQ ID NO: 1, for the treatment of various neuropsychiatric disorders, including Parkinson's disease, epilepsy, essential tremor, depression, anxiety disorders, and unconsciousness.

公开(公告)号：US12042507B2

公开(公告)日：2024-07-23

申请号：US17181921

申请日：2021-02-22

申请人： University of Georgia Research Foundation, Inc.

发明人： Hang Yin ,  Liwei Xie ,  Amelia Yao-Ye Yin

IPC分类号： A61K31/7105 ,  A61K9/00 ,  A61K31/015 ,  A61K31/277 ,  A61P21/04 ,  A61P25/14 ,  C12Q1/6876

CPC分类号： A61K31/7105 ,  A61K9/0019 ,  A61K31/015 ,  A61K31/277 ,  A61P21/04 ,  A61P25/14 ,  C12Q1/6876

摘要： Compositions and methods for modulating HIF-2α to meditate of hypoxia signaling in satellite cells and applications thereof for improving skeletal muscle generation and repair are provided. For example, methods of enhancing, increasing, accelerating or/and otherwise improving skeletal muscle generation or regeneration in a subject in need thereof are disclosed. In some embodiments, the methods include administering the subject an effective amount of HIF-2α inhibitor. The HIF-2α inhibitor can be effective to, for example, increase muscle satellite cell proliferation, differentiation, or a combination thereof in a subject. Composition and methods for improving respiration, and reducing or preventing the development or progression of fibrosis are also provided. The disclosed compositions and methods are particularly useful for treating muscular dystrophies, myopathies, and other muscle-related diseases and disorders.

公开(公告)号：US12024509B2

公开(公告)日：2024-07-02

申请号：US16814328

申请日：2020-03-10

申请人： C4X Discovery Limited

发明人： Emma Louise Blaney ,  Barrie Phillip Martin ,  Thorsten Nowak ,  Martin John Watson

IPC分类号： C07D471/04 ,  A61K31/4192 ,  A61K31/435 ,  A61K31/4439 ,  A61K31/47 ,  A61P3/04 ,  A61P19/10 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/32 ,  A61P25/34 ,  A61P25/36 ,  A61P43/00 ,  C07C233/69 ,  C07C233/78 ,  C07C275/28 ,  C07C275/40 ,  C07D213/63 ,  C07D213/64 ,  C07D213/74 ,  C07D231/38 ,  C07D235/26 ,  C07D235/30 ,  C07D239/34 ,  C07D239/42 ,  C07D239/80 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

CPC分类号： C07D471/04 ,  C07C233/69 ,  C07C233/78 ,  C07C275/28 ,  C07C275/40 ,  C07D213/63 ,  C07D213/64 ,  C07D213/74 ,  C07D231/38 ,  C07D235/26 ,  C07D235/30 ,  C07D239/34 ,  C07D239/42 ,  C07D239/80 ,  C07D239/84 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

摘要： The present invention relates to compounds that are inhibitors of the orexin-1 receptor. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with orexin-1 receptor activity.

公开(公告)号：US20240099987A1

公开(公告)日：2024-03-28

申请号：US18380680

申请日：2023-10-17

申请人： BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD.

发明人： AHARON M. EYAL ,  NOA RAZ

IPC分类号： A61K31/015 ,  A61K31/01 ,  A61K31/05 ,  A61K31/352 ,  A61K47/06 ,  A61K47/10 ,  A61K47/38 ,  A61P11/06 ,  A61P21/04 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P35/00

CPC分类号： A61K31/015 ,  A61K31/01 ,  A61K31/05 ,  A61K31/352 ,  A61K47/06 ,  A61K47/10 ,  A61K47/38 ,  A61P11/06 ,  A61P21/04 ,  A61P25/00 ,  A61P25/08 ,  A61P25/14 ,  A61P25/16 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P35/00

摘要： A composition of at least one cannabinoid, at least one terpene of pinene, limonene, linalool, caryophyllene, myrcene, humulene, terpineol, nerolidol, bisabolol, geraniol, borneol, eucalyptol in a concentration of at least about 20 wt % of terpenes in the composition, or at least two terpenes in a combined amount of at least about 40 wt % of terpenes in the composition, at least 5% by weight of a non-cannabinoid, non-terpene carrier, less than 5% by weight glycol, and less than 20% by weight water, and where the non-cannabinoid, non-terpene carrier comprises a) at least 5% by weight cellulose and the total terpenes to total cannabinoids weight/weight ratio in the composition is from 0.1 to 1.0, or b) less than 5% by weight cellulose and the total terpenes to total cannabinoids weight/weight ratio is from 0.05 to 1.0, obtained by providing and blending the cannabinoid and terpene in amounts configured to provide the ratio.

公开(公告)号：US20240000795A1

公开(公告)日：2024-01-04

申请号：US17945865

申请日：2022-09-15

申请人： Terran Biosciences Inc.

发明人： Sam CLARK

IPC分类号： A61K31/5513 ,  A61K31/519 ,  A61K31/554 ,  A61K45/06 ,  A61P25/14

CPC分类号： A61K31/5513 ,  A61K31/519 ,  A61K31/554 ,  A61K45/06 ,  A61P25/14

摘要： Provided herein are compositions relating to psychedelics and serotonin receptor modulators. Further provided herein are methods of suppressing or halting hallucinogenic effects of a psychedelic and methods of treating a disease or disorder (e.g., depression or diseases or disorders related to depression) comprising administering psychedelics and serotonin receptor modulators.

公开(公告)号：US11859020B2

公开(公告)日：2024-01-02

申请号：US17586185

申请日：2022-01-27

申请人： Northwestern University

发明人： Joseph R. Moskal ,  Jeffrey S. Burgdorf

IPC分类号： C07K7/06 ,  C07K7/08 ,  C07K7/64 ,  A61K38/00 ,  A61P25/22 ,  A61P25/24 ,  A61P25/08 ,  A61P25/28 ,  A61P25/18 ,  A61P25/00 ,  A61P25/14

CPC分类号： C07K7/64 ,  A61P25/14 ,  A61P25/22 ,  A61P25/24 ,  C07K7/08 ,  A61K38/00

摘要： Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders.

公开(公告)号：US11844794B2

公开(公告)日：2023-12-19

申请号：US17385450

申请日：2021-07-26

申请人： ADEPTIO PHARMACEUTICALS LIMITED

发明人： Andrew John Duffield ,  Anant Pandya

IPC分类号： A61K31/473 ,  A61K9/20 ,  A61K9/48 ,  A61P25/14 ,  C07D455/06 ,  C07D471/04 ,  A61K9/28

CPC分类号： A61K31/473 ,  A61K9/20 ,  A61K9/2846 ,  A61P25/14 ,  C07D455/06 ,  C07D471/04 ,  A61K9/48

摘要： The invention provides (+)-α-dihydrotetrabenazine succinate salt.
Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a pharmaceutically acceptable excipient and the uses of (+)-α-dihydrotetrabenazine succinate salt as a VMAT2 receptor antagonist and in the treatment of a movement disorder such as Tourette's syndrome.
The invention further provides a method for preparing the (+)-α-dihydrotetrabenazine succinate salt.

公开(公告)号：US11844786B2

公开(公告)日：2023-12-19

申请号：US15939828

申请日：2018-03-29

申请人： ADEPTIO PHARMACEUTICALS LIMITED

发明人： Andrew John Duffield ,  Anant Pandya

IPC分类号： A61K31/4375 ,  A61P25/14 ,  A61K31/435

CPC分类号： A61K31/435 ,  A61P25/14 ,  A61K2300/00

摘要： The invention relates to pharmaceutical compositions containing both (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine and their therapeutic uses, for example in the treatment of movement disorders, such as Tourette's syndrome.